ConnectiveRx and EagleForce recently announced a major partnership. They officially launched ShieldRx today. This powerful engine focuses on pharmacy misuse prevention. It vigilantly monitors networks, all while protecting sensitive health information.
Moreover, it immediately halts any activities that raise red flags. This proactive system secures payments before the claims process. Ultimately, it protects vital gross-to-net performance.
Currently, manufacturers face severe financial pressures. Payer tactics and accumulator programs drive these challenges. Meanwhile, growing pharmacy fraud demands immediate action. Therefore, traditional retrospective audits are no longer effective. Consequently, ShieldRx provides proactive, in-workflow protection. It successfully identifies questionable activity early. Thus, it blocks bad claims before payment occurs.
Advancing Pharmacy Misuse Prevention
ShieldRx joins ConnectiveRx’s robust Gross-to-Net Protection platform. This system combines expert affordability program design. It also utilizes real-time adjudication capabilities. Simultaneously, EagleForce provides advanced identity and compliance intelligence. Together, they deliver true pharmacy misuse prevention directly inside workflows. This integrated solution is the first of its kind.
Invalid copay behavior causes massive financial damage. Indeed, manufacturers lose five billion dollars annually. Therefore, developers built ShieldRx to tackle this problem directly. First, AI-driven risk models analyze massive data sets. They evaluate historical claims to spot abnormal behavior. Second, real-time risk scoring instantly flags suspect transactions. Third, high-speed evaluations return instant pass or fail decisions. Finally, pharmacists can access a dedicated resolution center quickly. Here, they handle immediate follow-up and documentation tasks.
By intercepting invalid activity, ShieldRx empowers manufacturers significantly. It securely safeguards valuable copay investments. Moreover, it strengthens overall program integrity. The system deploys seamlessly within existing pharmacy operations.
“Manufacturers are under unprecedented pressure to protect gross‑to‑net performance without disrupting patient access,” said Cindy Baksh, Chief Product Officer, ConnectiveRx. “ShieldRx sets a new standard for proactive oversight, giving brands real‑time protection, clearer insight, and greater confidence in the integrity of every claim.”
“ShieldRx represents a game-changing advancement in how manufacturers protect gross‑to‑net,” said Stanley Campbell, Jr. Chief Executive Officer, EagleForce. “By combining EagleForce’s real‑time identity and transaction intelligence with ConnectiveRx’s embedded pharmacy workflows and scale, manufacturers can identify and stop suspect behavior in seconds, before payment, without disrupting legitimate patient access.”
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
